Market Need The Presage ST2 Assay provides prognosis tools for heart failure and is cleared for risk stratification of chronic heart failure. Evidence from more than 31,000 subjects supports its clinical utility, making it attractive to cardiology departments, CHF clinics, and hospital laboratories seeking prognostic tools to guide therapy and resource allocation.

Strategic Partnerships With a lean team, scalable growth can come through partnerships with large diagnostic distributors and hospital systems. Channel partnerships can accelerate adoption in cardiology programs and CHF clinics, while collaboration with major market players can expand reach and credibility.

Regulatory Expansion Current clearance covers risk stratification of chronic heart failure; expanding indications would require additional regulatory approvals. Pursuing real world evidence programs can help build data to support broader use and payer coverage.

Value Proposition The high sensitivity ST2 assay enables personalized care by identifying high risk patients and guiding targeted therapies, which can reduce adverse events. A robust evidence base across thousands of subjects strengthens the case to hospitals and payers.

Data and Integration The technology stack including cloud infrastructure and web front ends offers opportunities for deeper hospital IT integration. Consider building HL7/FHIR compatible interfaces and clinician dashboards to surface risk status within workflows.